Initiator Pharma Management
Management criteria checks 4/4
Initiator Pharma's CEO is Claus Olesen, appointed in May 2016, has a tenure of 8.5 years. total yearly compensation is DKK1.29M, comprised of 66.2% salary and 33.8% bonuses, including company stock and options. directly owns 4.04% of the company’s shares, worth SEK14.67M. The average tenure of the management team and the board of directors is 8.7 years and 6 years respectively.
Key information
Claus Olesen
Chief executive officer
DKK 1.3m
Total compensation
| CEO salary percentage | 66.2% |
| CEO tenure | 8.5yrs |
| CEO ownership | 4.0% |
| Management average tenure | 8.7yrs |
| Board average tenure | 6yrs |
Recent management updates
Recent updates
We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn
May 31
Health Check: How Prudently Does Initiator Pharma (STO:INIT) Use Debt?
Feb 27Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?
May 20Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?
Jan 06We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn
Oct 26We're Not Very Worried About Initiator Pharma's (NGM:INIT) Cash Burn Rate
Jun 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -DKK 12m |
| Mar 31 2024 | n/a | n/a | -DKK 18m |
| Dec 31 2023 | DKK 1m | DKK 857k | -DKK 23m |
| Sep 30 2023 | n/a | n/a | -DKK 27m |
| Jun 30 2023 | n/a | n/a | -DKK 29m |
| Mar 31 2023 | n/a | n/a | -DKK 33m |
| Dec 31 2022 | DKK 1m | n/a | -DKK 38m |
| Sep 30 2022 | n/a | n/a | -DKK 40m |
| Jun 30 2022 | n/a | n/a | -DKK 43m |
| Mar 31 2022 | n/a | n/a | -DKK 34m |
| Dec 31 2021 | DKK 1m | n/a | -DKK 21m |
| Sep 30 2021 | n/a | n/a | -DKK 16m |
| Jun 30 2021 | n/a | n/a | -DKK 10m |
| Mar 31 2021 | n/a | n/a | -DKK 8m |
| Dec 31 2020 | DKK 936k | n/a | -DKK 9m |
| Sep 30 2020 | n/a | n/a | -DKK 10m |
| Jun 30 2020 | n/a | n/a | -DKK 9m |
| Mar 31 2020 | n/a | n/a | -DKK 9m |
| Dec 31 2019 | DKK 662k | n/a | -DKK 8m |
Compensation vs Market: Claus's total compensation ($USD180.57K) is about average for companies of similar size in the Swedish market ($USD234.97K).
Compensation vs Earnings: Claus's compensation has been consistent with company performance over the past year.
CEO
Claus Olesen (50 yo)
8.5yrs
Tenure
DKK 1,293,200
Compensation
Dr. Claus Elsborg Olesen is Chief Executive Officer at Stipe Therapeutics. He serves Chief Executive Officer at Initiator Pharma A/S since May 02, 2016 and serves as its Director since September 19, 2016 a...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 8.5yrs | DKK 1.29m | 4.04% SEK 14.7m | |
| Co-Founder & CTO | 8.8yrs | no data | no data | |
| Co-Founder | no data | no data | 1.16% SEK 4.2m | |
| Co-Founder & Chief Development Officer | no data | no data | 1.34% SEK 4.9m | |
| Chief Financial Officer | 8.8yrs | no data | no data | |
| Senior Vice President of Clinical and R&D Strategy & Portfolio Management | 3.9yrs | no data | no data | |
| Head of Clin Ops | no data | no data | no data | |
| Head of CMC | no data | no data | no data |
8.7yrs
Average Tenure
60yo
Average Age
Experienced Management: INIT's management team is seasoned and experienced (8.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 8.2yrs | DKK 1.29m | 4.04% SEK 14.7m | |
| Chairman of the Board of Directors | 8.2yrs | DKK 220.00k | 0.48% SEK 1.7m | |
| Director | 8.2yrs | DKK 90.00k | 0.25% SEK 897.2k | |
| Member of Scientific & Clinical Advisory Board | 3.9yrs | no data | no data | |
| Independent Director | 2.1yrs | DKK 90.00k | 0.034% SEK 122.5k | |
| Director | 3.8yrs | DKK 90.00k | 0.71% SEK 2.6m | |
| Director | 8.2yrs | DKK 90.00k | no data | |
| Member of Scientific & Clinical Advisory Board | 3.9yrs | no data | no data |
6.0yrs
Average Tenure
61.5yo
Average Age
Experienced Board: INIT's board of directors are considered experienced (6 years average tenure).